The cardiotoxic effects of adriamycin were studied in 399 patients treated for far-advanced carcimma. Forty-five patients (11%) exhibited transient electrocardiographs changes. Eleven others developed severe congestive heart failure. Eight of these latter patients died within 3 weeks of the onset of the cardiac decompensation. The diffuse nature of this myocardiopathy was suggested by: 1. a conspicuous decrease in the QRS voltage on the electrocardiograms; 2. rapidly occurring cardiac dilatation and ventricular failure, and 3. refractoriness to inoiropic drugs and mechanical ventricular assistance. Postmortem examination of the hearts in two cases showed a striking decrease in the number of cardiac: muscle cells present, degeneration of the remaining myocardial cells, loss o contractile substance, mitochondrial swelling, and intramitochondrial dense inclusion bodies. Congestive heart failure occurred only once in the 366 patients who were treated with less than 550 mg/m2 of adriamycin (0.27%), but there were 10 cases of cardiac failure in the 33 patients who received more than 550 mg/m2 of this drug (30%). Therefore, until more direct means are established to prevent adriamycin-induced congestive heart failure, it is suggested that the total dose of adriamycin should be limited to less than 550 mg/m2 to permit safer use of this efficacious cancer chemotherapeutic agent.

A clinicopathologic analysis of adriamycin cardiotoxicity

Adriamycin: A New Anticancer Drug with Significant Clinical Activity

Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide

PERHAPS no family of chemotherapeutic agents has been so rapidly accepted as a major therapeutic tool in treating patients with cancer as have the anthracyclines. Since the first clinical trials of...

The anthracycline antineoplastic drugs.

Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic.

On the components of secretion of mandibular glands of the ant .

Adriamycin (synonym doxorubicin) is a glycoside antibiotic whose structure and stereochemistry are represented in Fig. 1 (formula I). It consists of the tetracyclic quinoid aglycone adriamycinone (14-hydroxydaunomycinone) linked to the amino- sugar daunosamine. The chemical name for adriamycin is therefore the following: (7S : 9S)-9-hydroxyacetyl-4-methoxy-7,8,9,10-tetrahydro-6,7,9, ll-tetrahydroxy-7-0- (2′3′6′-trideoxy-3′-amino-α-L-lyxohexopyranosyl)-5,12-naphthacenedione.

A. Selva

Papers

Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic.

On the components of secretion of mandibular glands of the ant .

Structure and Physicochemical Properties of Adriamycin (Doxorubicin)

The structure of pederone a novel substance from (coleoptera staphylinidae).